I can't believe this still needs to be said (and more loudly): Trans rights are human rights.

And here is your accompanying editorial: Leveraging Single-Cell Profiling in Early-Phase Trials to Guide Rational Therapy Development url: academic.oup.com/neuro-oncolo...

Happy to share a new #NORLUX study on how humanized patient-derived xenografts of #glioblastoma can be useful in investigating immunosuppression and clinically-relevant immunotherapy testing. See for more: www.biorxiv.org/content/10.1... #immunotherapy, #preclinicalmodeling,

It was a great pleasure to learn about a recent discovery in ecDNA biology that answers the most critical question on ecDNA maintenance! @nature.com Are you a non-scientist? No worries! My team wrote a lay-audience-friendly summary about this exciting research finding! Check it out! rdcu.be/eQMvM

Very excited to have this collaborative work on evaluating PK/PD and single-cell responses for Ribociclib+Everolimus in #rGBM published. It was such a great experience working with @kevin-johnson.bsky.social and @roelverhaak.bsky.social. @ivycenter.bsky.social @anchitien.bsky.social

Delighted to share this new collaborative paper with the Ivy BTC where we performed deep characterization of glioma patients enrolled on a CDK4/6i Phase 0 trial academic.oup.com/neuro-oncolo... with @kevin-johnson.bsky.social @shwetalm.bsky.social @nadersanai.bsky.social

Sharks absolutely get cancer, and people claiming otherwise are pseudoscientific grifters preying on the desperate. Even if sharks did not get cancer, eating shark would not cure your cancer any more than eating LeBron James would make you better at basketball.

Senior Research Tech (Duke) – tumor immunobiology lab. Work with tumor/blood/CSF samples, culture patient-derived cell lines, assist single-cell assays, and support & lead research. Bio degree + research exp required. No visa sponsorship. Title may vary. Apply → careers.duke.edu/job-invite/2...

A new drug candidate for a difficult-to-treat type of lung cancer, developed by scientists in the Broad-Bayer oncology research alliance, targets HER2 mutations in lung cancer and shrinks tumors in mice and humans.

The immunology of brain tumors | Science Immunology www.science.org/doi/10.1126/... Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.

Today’s lab meeting is a debate of recent Nature/Science retraction decisions: fair or not? Important lesson that not all retractions are the same, authors not always to blame.

Almost half way to our fundraising target - and only two weeks to go! I'll be riding the 100 mile #CloserToFreeRide to raise money to support cancer research and patient care. Please consider donating - every penny counts! ➡️ www.rideclosertofree.org/participants... #CTFRide @ctfride.bsky.social

Devastating news. The Pediatric Brain Tumor Consortium has lost its ability to apply for federal funding upon which it is structured. Without this, it cant exist. This threatens access to clinical trials for children. These children need MORE funding and MORE trials, not less. They deserve better

🔥 Hot of the press in Neuro-Oncology! 🧠 #Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. academic.oup.com/neuro-oncolo... @eanoassociation.bsky.social @neuroonc.bsky.social

Findings from @roelverhaak.bsky.social et al. reveal lentiviral transduction + antibiotic selection dramatically ⬇️ ecDNA+ #cancer cells, revealing both a challenge for research and a potential therapeutic clue. #ecdna aacrjournals.org/cancerrescom... @aacrjournals.bsky.social

Happy to provide a comment on recent work by the Maciejowski lab on ecDNA inheritance www.cell.com/molecular-ce... and authors.elsevier.com/a/1lZPK3vVUP... - with Xue Jin

Excited to share our paper reporting significance of FGFR-alterations across pediatric gliomas. Congratulations April Apfelbaum and Eric Morin and to everyone across our labs and collaborators. Thank you to the foundations and patients/ families who made this happen. www.bandolab.org rdcu.be/eyHcG

PO just confirmed that our 5th percentile R01 is not getting funded. Past NCI Payline at 4 percent. Cant believe it.

Goldschmidt's hopeful monsters in cancer: single cell DNAseq shows whole genome doubling (WGD) is an ongoing and frequent mutational process in ovarian cancer. www.nature.com/articles/s41... beautiful work from @sohrabshah.bsky.social and team

New preprint on longitudinal treatment response signatures in IDH-mutant glioma from the GLASS Consortium www.biorxiv.org/content/10.1...

Together with friends and colleagues from #CMCO @yalecancer.bsky.social, @yalepathology.bsky.social, and further afield, we are the #CycloPaths Closer to Free Ride 🚲06 September 2025 💪100 miles #CTFRide Join our team, spread the word, sponsor us if you can www.rideclosertofree.org/participants...

After three days of engaged discussions, we wrapped up the 2025 Mark Foundation on Genomic Instability. What a fun event with amazing participants.

It's 102°F/39°C in New Haven—but 30 international experts have braved the heatwave to join us at @yaleschoolofmed.bsky.social for a 3-day workshop on chromosomal instability in cancer. Thank you to our workshop organizers @roelverhaak.bsky.social, Florian Markowetz, & Aurelie Ernst!

Excited to host nearly 30 international experts for the @themarkfdn.bsky.social workshop on genomic instability in cancer at @yaleschoolofmed.bsky.social today! This area of research is ready for the next breakthrough. @yalecancer.bsky.social

Resolving spatial subclonal genomic heterogeneity of loss of heterozygosity and extrachromosomal DNA in gliomas www.nature.com/articles/s41...

[email protected]: “We’re recognizing that we need a paradigm shift – that we need to approach the disease [#braincancer] differently than we have so far.” yalecancercenter.org/news-article... @theaacr.bsky.social #NCRM25 #unitedbycancerresearch #btsm

Excited to share our latest manuscript www.biorxiv.org/content/10.1... This was a great collaboration with Drs. Huse, Lang, @jesserdixon.bsky.social

Indigenous West Papuans claim Indonesian government is 'land grabbing' www.rnz.co.nz/internationa... West Papuans in Merauke claim the Indonesian government is stealing land to build its global "food barn" and feed its population of 280 million.

1/ Truly excited to share our new study that I had to privilege to co-lead during my PhD alongside great friends and collaborators @masashi-nomura.bsky.social, @kevin-johnson.bsky.social and Luciano Garofano, published at Nature Genetics @natureportfolio.nature.com! www.nature.com/articles/s41...

1/ Thrilled to share our TWO back-to-back papers published in Nature Genetics today! www.nature.com/articles/s41... , www.nature.com/articles/s41...

Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors www.cell.com/cell/abstrac...

I have never seen a conference session as oversubscribed as the Next-gen ADC session. Even the overflow room is overflowing. Clearly a flaming hot topic. #AACR25

I look forward to the educational session on ecDNA, Sat 1230p-2p in room S403 #AACR #AACR25

Well worded arguments why investment in biotech science is a no-brainer www.amjmed.com/article/S000...

Soccer tryouts (or any sports tryouts) are evil and an injustice to our kids.

PAPER OUT!! 🥳🎉💃🏻🕺🏻💃🏻🕺🏻 A redefined InDel taxonomy provides insights into mutational signatures @NatureGenet Brainchild of the amazing #GeneKoh (Sir Jeffrey Cheah ECR) Tweetorial below!! 👇 1/n www.nature.com/articles/s41...

Great example of how to do Phase 0/window of opportunity trials for glioblastoma: A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma www.science.org/doi/10.1126/...

My lab at hiring! - we have TWO postdoc positions (one computational, one wet lab focussed) at Yale @yaleschoolofmed.bsky.social, working closely with our group members at University of Cambridge, UK @cambridgeuni.bsky.social Please help to spread the word! Adverts with full details below ⬇️

Integrated Proteogenomic Characterization of Glioblastoma Evolution: Overcoming Barriers to Develop Personalized Treatment Strategies dailynews.ascopubs.org/do/integrate...

We are looking to recruit new postdocs! Please check verhaaklab.com/archive/2025....

Now online in Cancer Discovery: Spatial-Temporal Diversity of Extrachromosomal DNA Shapes Urothelial Carcinoma Evolution & Tumor-Immune Microenvironment - by Wei Lv, Yuchen Zeng, Conghui Li, Yuan Liang, Birgitte Regenberg, Yonglun Luo, Chunhua Lin, Peng Han, et al. doi.org/10.1158/2159... #ecDNA

New preprint from the lab - Selective depletion of cancer cells with extrachromosomal DNA via lentiviral infection www.biorxiv.org/content/10.1...

Programs, origins and immunomodulatory functions of myeloid cells in glioma | @nature.com www.nature.com/articles/s41...

📣 Open computational PhD & Postdoc positions! Excited about the open positions as part of our newly funded Emmy Noether Group are online now under kocakavuklab.vercel.app/joinus 📢 Please RT (what's the bsky equivalent here?) and distribute ! 👇A quick instruction on how to apply

Consider adding your voice chng.it/NsJDWRzSp4

1. Today the NIH director issued a new directive slashing overhead rates to 15%. I want to provide some context on what that means and why it matters. grants.nih.gov/grants/guide...

What an absolute pleasure to host my mentor @roelverhaak.bsky.social at our West German Cancer Center in Essen today. Fantastic talk in a packed room on #WorldCancerDay2025.

Vaccin critic Memoli becomes the acting NIH Director - we are in for a ride www.niaid.nih.gov/research/mat...

Great conference with expert lineup ! I look forward to attending! 🔥🔥👇🏻👇🏻

Targeting tumor micro environment: "Multiplex universal combinatorial immunotherapy via gene silencing (MUCIG), which uses CRISPR–Cas13d to silence multiple endogenous immunosuppressive genes in the TME, promoting TME remodeling and enhancing antitumor immunity." news.yale.edu/2025/01/16/m...